reactions to tirzepatide Bumps and humps in the success of as the first GLP1 and GIP receptor agonist Tirzepatide reduces food intake and

Case description : A 60-year-old female with a history of estrogen receptor-positive breast cancer presented with significant weight gain following adjuvant endocrine therapy

In a phase 3 trial (OASIS 4) comparing oral semaglutide 25 mg (the Wegovy pill) to placebo, the most common side effects were: Nausea Vomiting Constipation Indigestion (dyspepsia) Diarrhea Most side effects were mild or moderate and went away without stopping treatment

Mechanism of Action GLP-1 agonists exert their effects through multiple mechanisms, all of which contribute to their therapeutic benefits

Fully diagnosing macular degeneration typically involves a comprehensive eye examination